Pharmaceutical

Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics’s CTX-112?

CTX-112 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Marginal Zone B-cell Lymphoma.

Jul 2, 2024 - 04:00
CTX-112 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Marginal Zone B-cell Lymphoma.
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07...

Next Article

Risk adjusted net present value: What is the current valuation of Pfizer’s Influ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

ESMO 2023: MSD’s Welireg leads HIF-2α inhibitors in RCC despite unclear OS

ESMO 2023: MSD’s Welireg leads HIF-2α inhibitors in RCC...

Oct 23, 2023

STAT+: Brazilian government advisory committee says a Vertex cystic fibrosis drug is not cost-effective and should not be reimbursed

STAT+: Brazilian government advisory committee says a V...

Apr 7, 2023

Kymera’s novel MDM2 degrader granted orphan designation for AML

Kymera’s novel MDM2 degrader granted orphan designation...

Jun 23, 2023